60岁及以上帕金森病患者左旋多巴诱发运动障碍发生率及相关因素分析  

Incidence of levodopa-induced dyskinesia in ederly patients with Parkinson＇s disease and related factors

作　　者：李淑华[1] 苏闻[1] 曾湘豫[1] 陈海波[1] 蔡晓杰[1] 

机构地区：[1]北京医院神经内科,100730

出　　处：《中华全科医师杂志》2016年第1期53-55,共3页Chinese Journal of General Practitioners

摘　　要：采用横断面研究对100例以复方左旋多巴为主要治疗的60岁及以上帕金森病患者进行一般状况、用药情况、统一帕金森病评分量表检查及左旋多巴诱发运动障碍（LID）出现率调查。本组患者LID发生率为37％，服用复方左旋多巴4年以上者LID的发生率高于服用复方左旋多巴4年以下者（55％与26％，X2=8．770，P=0．003）；震颤为主型PD患者“剂峰”运动障碍发生率低于强直少动为主型（X2=4．399，P=0．036）。LID主要与复方左旋多巴服用时间有关，金刚烷胺有可能降低“关期”肌张力障碍的发生率。One hundred patients with Parkinson＇s disease （PD） aged 60 and above treated with levodopa were enrolled in this cross section study. The general conditions, medication, unified Parkinson＇s disease rating scale （UPDRS） scores and the incidence of levodopa-induced dyskinesia （LID） were documented. The incidence rate of LID in this group of PD patients was 37.0% （37/100）. The incidence was significantly higher in patients with levodopa treatment 〉I 4 years than that in patients with levodopa treatment 〈4 years （55% vs. 26% , X2 = 8. 770, P = 0. 003）. The incidence rate of ＂peak dosage＂ dyski0esia in tremor-dominant PD patients was lower than that in rigidity-dominant PD patients （X2 = 4. 399, P =0. 036）. The incidence rate of LID was correlated with the duration of levodopa therapy. Amantadine may reduce the incidence of ＂off＂ dystonia.

关 键 词：运动障碍 药物性 帕金森病 左旋多巴 

分 类 号：R742.5[医药卫生—神经病学与精神病学]